May 5th 2024
Data from a phase 2 study may support apalutamide plus androgen deprivation in high-risk localized prostate cancer following radical prostatectomy.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
PRESIDE Trial Meets Primary End Point With Continuous Enzalutamide After Progression of mCRPC
February 18th 2022The phase 3b PRESIDE trial showed significant progression-free survival improvement when men with chemotherapy-naïve metastatic castration-resistant prostate cancer were treated with a regimen of continuous enzalutamide vs placebo.
Efstathiou Discusses Background of Niraparib Combo in HHR-Altered mCRPC From MAGNITUDE Trial
February 17th 2022Eleni Efstathiou, MD, PhD, spoke about the treatment combination of niraparib plus abiraterone acetate and prednisone for the treatmeant of men with metastatic castration-resistant prostate cancer in the phase 3 MAGNITUDE trial.
FDA Grants Breakthrough Device Designation to Blood Test for Detecting Early-Stage Prostate Cancer
February 17th 2022Datar Cancer Genetics announced that its TriNetra-Prostate blood test, which was developed to detect early-stage prostate cancer, received breakthrough device designation from the FDA.
FDA Approves TLX591-CDx Prostate Cancer Imaging Product, Making 68Ga-based PSMA-PET More Accessible
December 20th 2021The decision by the FDA to approve prostate cancer imaging product TLX591-CDx, a kit to aid in the preparation of gallium-68 gozetotide injections, should make 68Ga-based PSMA-PET more broadly accessible.
Optimization of Genetic Testing for mCRPC
Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.
Role of PSMA PET Imaging in mCRPC
Prostate cancer experts review the use of PSMA PET/CT imaging and Axumin imaging for patients with metastatic castration-resistant prostate cancer.
Patient Case #2: Choosing Optimal Therapy in mCRPC
Raoul S. Concepcion, MD, presents the case of a 64-year-old-man with mCRPC, and Jason M. Hafron, MD, CMO, leads the discussion on the optimal treatment approach for the given case.